[渐进性肌性:疾病的多样性和临床实践中的关键点]
Maya Tojima1, Katsuya Kobayashi, Haruhisa Inoue
1Department of Neurology, Kyoto University Graduate School of Medicine.
Brain and nerve = Shinkei kenkyu no shinpo
|May 12, 2025
概括
渐进性肌痛性 (PME) 是一种罕见的神经系统疾病,导致肌痛和发作. 这篇评论详细介绍了它们的遗传原因,诊断和当前治疗策略,以获得更好的患者结果.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 罕见疾病 罕见疾病
背景情况:
- 渐进性肌性 (PMEs) 是一种罕见的神经系统疾病的异质群.
- 它的特征是渐进的肌肉,,小脑功能障碍和认知能力下降.
- 包括遗传疾病,如拉福拉病和Unverricht-Lundborg病.
研究的目的:
- 为PMEs提供全面的概述.
- 突出临床特征,遗传基础和诊断方法.
- 审查最近的治疗进步和挑战.
主要方法:
- 关于 PME 研究的文献综述.
- 对临床,遗传和病理学数据的分析.
- 评估诊断标准和治疗选择.
主要成果:
- 这种PME呈现出一系列明显的渐进性神经症状.
- 不同的PME亚型的基础是各种基因突变.
- 诊断依赖于临床表现,家族病史和专业测试.
- 症状治疗是标准的,有些药物表现有前途.
结论:
- 小微企业代表着一组多样化的具有挑战性的遗传神经疾病.
- 准确的诊断对于适当的管理至关重要.
- 目前正在进行的研究旨在发现PMEs的新型治疗点.
相关概念视频
Seizures: Classification
284
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
284
Arteries of the Lower Limbs
166
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
166
Disorders of the Skeletal Muscle
828
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
828
Antiepileptic Drugs: Glutamate Antagonists
249
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
249
Antiepileptic Drugs: Potassium Channel Activators
126
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
126
Antiepileptic Drugs: GABAergic Pathway Potentiators
260
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
260


